Central Admixture Pharmacy Services Microplegia Solution, HIGH POTASSIUM (100 mEq) recall — FDA D-0677-2023
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Complete FDA and NHTSA recall records dated in May 2023.
These records include useful source details for the selected month.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.